Peter Johnson, MD, obtained his medical degree from Cambridge University and St Thomas’s Medical School in 1982 and further specialized in oncology at St Bartholomew’s Hospital, where he completed an Imperial Cancer Research Fund Clinical Research Fellowship in 1994. Prof. Johnson further trained as a Senior Lecturer in Medical Oncology at the ICRF Cancer Medicine Research Unit, Leeds, where he also became the Chair of Medical Oncology in Southampton in 1998.
Today, Prof. Johnson teaches at the University of Southampton and is a practicing Oncologist at the Southampton University Hospitals NHS Trust. His specialties lie in the treatment of lymphoma and he is the Chief Investigator for several lymphoma trials nationwide.
Speaking on the use of immunostimulatory antibodies in lymphoma
Prof. Johnson focuses his research on immunotherapy in Hodgkin and non-Hodgkin lymphoma. His most recent international trial includes the RATHL study which investigates the use of fluorodeoxyglucose (FDG)-positron emission tomography (PET)-guided treatment escalation or de-escalation for optimum levels of efficacy and safety. Prof. Johnson also led the REModL-B study investigating the use of real-time gene expression profiling to personalize treatment of diffuse large B-cell lymphoma. Currently, Prof. Johnson is the Chief investigator in a Phase I trial of anti-CD40 antibody activity in antigen presentation and possible anti-tumor effects.